11423SOS-AMIOpenMulti-center, double-blind, randomized, placebo-controlled, parallel-group study to
evaluate the efficacy and safety of self-administered subcutaneous selatogrel for
prevention of all-cause death and treatment of acute myocardial infarction in
subjects with a recent history of acute myocardial infarctionNCT04957719IndustryAdultTreatmentOtherWaksman, RonMedstar Washington Hospital CenterMCRN - Wash Interventional2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>